Intravesical CAR T Therapy Shows Promise in Bladder Cancer Treatment

Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center, and Roswell Park Comprehensive Cancer Center have developed genetically engineered CAR T cells that specifically target bladder cancer cells. The study, published in the Journal of Experimental Medicine, demonstrates the efficacy of these cells in controlling bladder tumors in mouse models.
The research highlights the use of intravesical delivery, where CAR T cells are administered directly into the bladder via a catheter. This method allows for localized treatment, minimizing systemic exposure and associated toxicities. This approach contrasts with traditional systemic infusion, which can lead to broader side effects.
Bladder cancer is a significant health concern, with approximately 600,000 new cases diagnosed globally each year, including about 80,000 in the United States. Current treatments often involve radical cystectomy followed by chemotherapy or immunotherapy, which can have severe and life-altering consequences.
Jedd Wolchok from Weill Cornell Medicine noted that the compartmentalized delivery system used in this study could pave the way for broader use of CAR T cells in treating solid tumors like bladder cancer. Taha Merghoub emphasized that targeting MUC16, a protein expressed in bladder cancer cells, offers a promising therapeutic option for patients with limited alternatives.